- In April 2025, Organon has acquired U.S. rights to TOFIDENCE, a tocilizumab biosimilar to ACTEMRA, from Biogen. This strengthens Organon’s biosimilars portfolio in immunology, expanding treatment options for arthritis and COVID-19. TOFIDENCE, launched in May 2024, treats multiple inflammatory conditions and supports growth in Organon’s biosimilars business with significant market potential
- In November 2023 ,CooperCompanies has acquired select Cook Medical assets for USD 300 million, enhancing its women’s health and surgical portfolio under CooperSurgical. The deal includes products like the Bakri Balloon and Doppler monitors. Expected to boost revenue and earnings in 2024, the acquisition strengthens Cooper’s global position in fertility and gynecologic healthcare
